Maven Securities’s Travere Therapeutics TVTX Stock Holding History

Maven Securities’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-105,998	Closed	-$1.57M	–	1275
2021 Q2	$1.57M	Buy	105,998 +19,023	+22%	+$375K	0.06%	291
2021 Q1	$2.15M	Buy	86,975 +42,069	+94%	+$1.16M	0.1%	205
2020 Q4	$1.24M	Buy	+44,906	New	+$1.05M	0.12%	206
2020 Q3	–	Sell	-170,000	Closed	-$3.47M	–	754
2020 Q2	$3.47M	Buy	+170,000	New	+$2.71M	0.24%	71

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Maven Securities's TVTX Position: Q3 2021 in Review

Maven Securities sold out of Travere Therapeutics (TVTX) in Q3 2021, closing a stake of 105,998 shares — an estimated $1.57M sold.

Maven Securities first reported a position in TVTX in Q2 2020 and held it in 4 quarters. The position peaked at $3.47M in Q2 2020. 148 funds tracked by Wall St. Rank hold TVTX as of Q3 2021.

Maven Securities reported no remaining Travere Therapeutics position as of Q3 2021 after selling out during the quarter.
Maven Securities sold 105,998 Travere Therapeutics shares in Q3 2021, an estimated $1.57M.
Maven Securities first reported a position in Travere Therapeutics in Q2 2020 and held it in 4 quarters.
Maven Securities's Travere Therapeutics position peaked at $3.47M in Q2 2020.
148 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.